Document is current
Any future updates will be listed below
-
Authors
Maslah, Nabih https://orcid.org/0000-0002-5553-462X
Kaci, Nina
Roux, Blandine
Alexe, Gabriela https://orcid.org/0000-0002-5668-6297
Marie, Raphael
Pasquer, Hélène
Verger, Emmanuelle https://orcid.org/0000-0002-2773-2784
De Oliveira, Rafael Daltro
Culeux, Cécile
Mlayah, Bochra
Gauthier, Nicolas
Gonzales, Fanny
Zhao, Lin-Pierre https://orcid.org/0000-0001-5035-4470
Ganesan, Saravanan https://orcid.org/0000-0002-5773-1715
Gou, Panhong
Ling, Frank
Soret-Dulphy, Juliette
Parquet, Nathalie
Vainchenker, William https://orcid.org/0000-0003-4705-202X
Raffoux, Emmanuel https://orcid.org/0000-0003-3925-7391
Padua, Rose Ann
Giraudier, Stéphane
Marty, Caroline https://orcid.org/0000-0003-4350-2302
Plo, Isabelle
Lobry, Camille https://orcid.org/0000-0003-0550-4921
Stegmaier, Kimberly https://orcid.org/0000-0003-0218-7895
Puissant, Alexandre https://orcid.org/0000-0002-3997-9282
Kiladjian, Jean-Jacques
Cassinat, Bruno https://orcid.org/0000-0002-6514-3905
Benajiba, Lina https://orcid.org/0000-0001-5440-1115
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 7 June 2025
First Online: 8 July 2025
Competing interests
: L.B. received research funding from Gilead and Pfizer for unrelated projects, and personal fees from BMS, Novartis and GSK outside of the submitted work. N.G. received personal fees from Novartis, Abbvie and Astra Zeneca outside of the submitted work. K.S. is on the SAB and has stock options in Auron Therapeutics and received grant funding from Novartis and KronosBio on topics unrelated to this manuscript. The remaining authors declare no competing interests.
